journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/29309357/expressions-and-clinical-significance-of-her4-and-cd44-in-sinonasal-mucosal-malignant-melanoma
#1
Wenjia Zhu, Shimin Li, Bingqing Zou, Hongqin Liu, Shuyi Wang
Sinonasal mucosal malignant melanoma (SNMMM) is a rare disease. The aim of this study was to investigate the expressions of HER4 and CD44 in human SNMMM tissues and their relationship with the clinicopathological features and prognosis of patients. In total, 64 paraffin-embedded samples of SNMMM treated in our hospital from 29 December 1999 to 24 June 2011 were collected. HER4 and CD44 were detected in the tissues of SNMMM by immunohistochemistry. The differences in the HER4 and CD44 expressions in the tissues were evaluated and matched with clinicopathological parameters and the survival rate, respectively...
January 5, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29303890/comparative-outcomes-and-toxicities-for-ruthenium-106-versus-palladium-103-in-the-treatment-of-choroidal-melanoma
#2
Hasan Danish, Matthew J Ferris, Ehsan Balagamwala, Jeffrey M Switchenko, Kirtesh R Patel, Maria Choudhary, Caroline Craven, Pia Mendoza, John Suh, Chris Bergstrom, Hans E Grossniklaus, Thomas M Aaberg, Arun Singh, Ian R Crocker, Mohammad K Khan
For the treatment of choroidal melanoma, palladium-103 (Pd) and ruthenium-106 (Ru) plaque brachytherapy shows reduced toxicity compared with the historical standard iodine-125. No report has directly compared the clinical outcomes between Pd and Ru, and the reasons for the selection of one over the other remain purely theoretical. Patients with choroidal melanoma with apical tumor height up to 5 mm were included. Patients from Emory University were treated with Pd between 1993 and 2012. Patients from Cleveland Clinic were treated with Ru between 2005 and 2010...
January 3, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29266020/a-novel-kras-mutation-in-metastasic-conjunctival-melanoma-a-case-report-and-literature-review
#3
Luis P Del Carpio Huerta, Maria Mas Castells, Georgia Anguera Palacios, Ivana Sullivan, Alan Gonzalez Vidal, Margarita Majem Tarruella
Conjunctival melanoma is a rare disease, and little is known about its molecular background. Here, we present the case of a 48-year-old patient with conjunctival melanoma and metachronic lymph node and skin metastasis with KRAS p.K117Y mutation in exon 4 in all the lesions. The cancer genome interpreter predicted this mutation to have driver function. To our knowledge, this is the first time this mutation is found in conjunctival melanoma. An important role in the disease development is suggested.
December 20, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29261570/quality-of-life-patient-reported-outcomes-for-locally-advanced-cutaneous-melanoma
#4
Evan S Weitman, Matthew Perez, John F Thompson, Robert H I Andtbacka, Jo Dalton, Mona L Martin, Talia Miller, Chad Gwaltney, David Sarson, Eric Wachter, Jonathan S Zager
Locally advanced cutaneous melanoma has marked quality-of-life implications; however, the patient experience of symptom management and subsequent impact on quality of life has not been well described. This study aims to address the impact on patients of advanced cutaneous melanoma through qualitative interviews. Adults with stage IIIB, IIIC, or IV (M1a) cutaneous melanoma were recruited from two cancer centers in the USA and one in Australia. Telephone interviews were conducted to assess how locoregionally advanced cutaneous melanoma impacted everyday life...
December 19, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29232305/braf-inhibitors-can-exert-control-of-disease-in-braf-t599i-mutated-melanoma-a-case-report
#5
Susanna Gallo, Valentina Coha, Daniela Caravelli, Paolo Becco, Tiziana Venesio, Alessandro Zaccagna, Elena Giacone, Federica Marenco, Alberto Pisacane, Manuela Racca, Loretta Gammaitoni, Massimo Aglietta, Fabrizio Carnevale-Schianca
BRAF signaling is involved in melanoma growth in more than half of metastatic patients. In the last few years, new drugs that block this pathway have significantly improved the outcomes of patients with metastatic melanoma. Ninety percent of BRAF mutations involve exon 15, and the most frequent, V600E, results from the amino acid change from valine (V) to glutamic acid (E). BRAF inhibitor treatments have shown a notable overall response rate and improvements in progression-free and overall survival. Rare BRAF mutations of codon 599 have been also described in a few patients with papillary thyroid cancer and melanoma...
December 11, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29232304/rapid-braf-mutation-tests-in-patients-with-advanced-melanoma-comparison-of-immunohistochemistry-droplet-digital-pcr-and-the-idylla-mutation-platform
#6
Cornelis Bisschop, Arja Ter Elst, Lisette J Bosman, Inge Platteel, Mathilde Jalving, Anke van den Berg, Arjan Diepstra, Bettien van Hemel, Gilles F H Diercks, Geke A P Hospers, Ed Schuuring
BRAF mutational testing has become a common practice in the diagnostic process of patients with advanced melanoma. Although time-consuming, DNA sequencing techniques are the current gold standard for mutational testing. However, in certain clinical situations, a rapid test result is required. In this study, the performance of three rapid BRAF mutation tests was compared. Thirty-nine formalin-fixed paraffin-embedded melanoma tissue samples collected between 2007 and 2014 at a single center were included. These samples were analyzed by immunohistochemistry using the anti-BRAF-V600E (VE1) mouse monocolonal antibody (BRAF-VE1 IHC), a V600E-specific Droplet Digital PCR Test, and the Idylla BRAF- Mutation Test (Idylla)...
December 11, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29227334/quantitative-assessment-of-neuropilin-2-as-a-simple-and-sensitive-diagnostic-assay-for-spitzoid-melanocytic-lesions
#7
Anna Eisenstein, Izabela P Panova, Hye J Chung, Lynne J Goldberg, Qing Zhang, Rossitza Lazova, Jag Bhawan, Klaus J Busam, James T Symanowski, Rhoda M Alani, Byungwoo Ryu
There is a significant need for the development of diagnostic tools that can precisely distinguish Spitz nevi and spitzoid melanomas. Here, we report the development of a PCR-based quantitative diagnostic assay for spitzoid melanocytic lesions utilizing the expression ratio of neuropilin-2 and melan-A genes in primary tumor specimens. We find that the expression ratio of neuropilin-2/melan-A is significantly increased in spitzoid melanomas compared with Spitz nevi. The diagnostic potential of this quantitative assay was validated in two independent sets of patient samples as demonstrated in a receiver operating characteristic curve analysis showing an area under the curve value of 91...
December 8, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29227333/illustrative-cases-for-monitoring-by-quantitative-analysis-of-braf-nras-ctdna-mutations-in-liquid-biopsies-of-metastatic-melanoma-patients-who-gained-clinical-benefits-from-anti-pd1-antibody-therapy
#8
Teofila Seremet, Simon Planken, Max Schreuer, Yanina Jansen, Mélanie Delaunoy, Hakim El Housni, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns
Anti-programmed death 1 (PD-1) monoclonal antibodies improve the survival of metastatic melanoma patients. Predictive or monitoring biomarkers for response to this therapy could improve the clinical management of these patients. To date, no established biomarkers are available for monitoring the response to immunotherapy. Tumor- specific mutations in circulating tumor DNA (ctDNA) such as BRAF and NRAS mutations for melanoma patients have been proposed for monitoring of immunotherapy response. We present seven illustrative cases for the use of ctDNA BRAF and NRAS mutations' monitoring in plasma...
December 8, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29215399/hemorrhage-of-liver-and-bone-metastases-as-a-result-of-rapid-response-to-dual-braf-mek-inhibition-in-metastatic-melanoma-a-case-report
#9
Tine Loyson, Emilie Werbrouck, Kevin Punie, Lawrence Bonne, Vincent Vandecaveye, Oliver Bechter
Combination therapy using a BRAF and MEK inhibitor significantly improves both progression-free and overall survival in patients with BRAF V600-mutated stage IV melanoma. Dual MAPK inhibition achieves an objective response in the majority of patients. We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases. The patient commenced dabrafenib and trametinib with clinical and biochemical signs of response after 2 days. On day 3 she developed grade 3 liver hemorrhage, which was successfully embolized...
December 5, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29200095/widespread-spontaneous-hyperproliferation-melanosis-and-melanoma-in-hgf-cdk4r24c-mice
#10
Louise van der Weyden, Mark J Arends, Thomas Brenn, Thomas Tuting, David J Adams
No abstract text is available yet for this article.
December 1, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29176501/phase-iiib-safety-results-from-an-expanded-access-protocol-of-talimogene-laherparepvec-for-patients-with-unresected-stage-iiib-ivm1c-melanoma
#11
Jason Chesney, Sanjay Awasthi, Brendan Curti, Laura Hutchins, Gerald Linette, Pierre Triozzi, Marcus C B Tan, Russell E Brown, John Nemunaitis, Eric Whitman, Christopher Windham, Jose Lutzky, Gerald F Downey, Nicolas Batty, Thomas Amatruda
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We aim to describe the safety of talimogene laherparepvec. Intralesional talimogene laherparepvec was administered at less than or equal to 4 ml×10 PFU/ml at protocol day 1, then less than or equal to 4 ml×10 PFU/ml 21 days later, and then every 14 days. Treatment continued until complete response, absence of injectable tumors, progressive disease, intolerance, or US Food and Drug Administration approval...
November 22, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29140834/prognostic-factors-in-patients-with-metastatic-spinal-cord-compression-secondary-to-melanoma-a-systematic-review
#12
Nicholas J Hadden, Jerome R D McIntosh, Samuel Jay, Paula J Whittaker
Melanoma is one of the most common primary tumours associated with metastatic spinal cord compression (MSCC). The aim of this review is to identify prognostic factors specifically for MSCC secondary to melanoma. A systematic search of literature was performed in MEDLINE, Embase and the Cochrane Library to identify studies reporting prognostic factors for patients with MSCC secondary to melanoma. Two studies, involving a total of 39 patients, fulfilled the inclusion criteria. The variables associated with increased survival were receiving postoperative radiotherapy, receiving chemotherapy, perioperative lactate dehydrogenase level less than or equal to 8...
November 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29140833/immune-checkpoint-inhibitor-therapy-in-a-liver-transplant-recipient-with-a-rare-subtype-of-melanoma-a-case-report-and-literature-review
#13
James C Kuo, Leslie B Lilly, David Hogg
Immunotherapy with immune checkpoint inhibitors (ICIs) may be considered as a treatment option for various types of tumors, but the transplant recipient population as well as patients requiring long-term systemic immunosuppression for other reasons have been systematically excluded from clinical trials involving ICIs. We report a case of successful treatment with ICI in a liver transplant recipient diagnosed with a rare subtype of melanoma. This patient had not required any modification to her antirejection immunosuppression before or during immunotherapy, had not experienced any serious immune-related adverse event, and had a durable objective response for nearly 1...
November 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29135861/in-vitro-and-in-vivo-antimelanoma-effect-of-ethyl-ester-cyclohexyl-analog-of-ethylenediamine-dipropanoic-acid
#14
Andjelka M Isakovic, Sasa M Petricevic, Slavica M Ristic, Dusan M Popadic, Tamara K Kravic-Stevovic, Nevena S Zogovic, Jelena M Poljarevic, Tatjana V Zivanovic Radnic, Tibor J Sabo, Aleksandra J Isakovic, Ivanka D Markovic, Vladimir S Trajkovic, Sonja T Misirlic-Dencic
Melanoma, an aggressive skin tumor with high metastatic potential, is associated with high mortality and increasing morbidity. Multiple available chemotherapeutic and immunotherapeutic modalities failed to improve survival in advanced disease, and the search for new agents is ongoing. The aim of this study was to investigate antimelanoma effects of O,O-diethyl-(S,S)-ethylenediamine-N,N'di-2-(3-cyclohexyl) propanoate dihydrochloride (EE), a previously synthesized and characterized organic compound. Mouse melanoma B16 cell viability was assessed using acid phosphatase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, sulforhodamine B, and lactate dehydrogenase assays...
November 13, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29120964/analysis-of-survival-of-patients-treated-with-vemurafenib-ipilimumab-and-dabrafenib-for-advanced-skin-melanoma-in-daily-clinical-practice-real-world-data-retrospective-analysis-of-patients-treated-under-drug-reimbursement-programmes-in-poland-in-2013-2016
#15
Melania Brzozowska, Waldemar Wierzba, Andrzej Śliwczyński, Marcin Świerkowski, Piotr Potemski, Michał Marczak
Vemurafenib, ipilimumab and dabrafenib were registered for the treatment of advanced skin melanoma pursuant to the results of randomized phase III clinical trials. Real-world data on survival time for patients treated with those drugs in daily clinical practice are so far limited. Patients with advanced skin melanoma treated under reimbursement programmes (drug programmes), for which they were qualified pursuant to uniform inclusion criteria in force in all oncology centres in Poland. Data were obtained from the electronic databases of the national payer (NFZ) responsible for the implementation and monitoring of reimbursement (drug) programmes...
November 8, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076925/circulating-epithelial-tumor-cells-as-a-prognostic-tool-for-malignant-melanoma
#16
Katharina Pachmann, Regina Willecke-Hochmuth, Katrin Schneider, Martin Kaatz
Although immune therapies with checkpoint inhibitors have gained increasing attention in advanced and metastatic melanoma, interferon-α remains a standard therapy for nonmetastatic malignant melanoma with risk factors. Interferons can successfully prevent relapse; however, the response rate is still not as high as would be desired. Prognostic tools to predict the response are required, which could lead to more individualized treatment regimens. In numerous studies over the past decade, circulating epithelial tumor cells (CETCs) have been shown to be a promising biomarker for estimating the risk of metastatic relapse, and we sought to determine whether they can also be used for this purpose in malignant melanoma...
October 25, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076924/overexpression-of-mrna-decapping-enzyme-1a-predicts-disease-specific-survival-in-malignant-melanoma
#17
Yong Tang, Chao Xie, Yu Zhang, You Qin, Weikang Zhang
Our previous study identified that rs11551405 A allele located at the 3' UTR of mRNA-decapping enzyme 1a (DCP1A) was associated with an increased risk for malignant melanoma (MM). The aim of this study was to investigate whether that association is manifested at the DCP1A expression and whether an altered DCP1A expression can predict disease-specific survival (DSS) of MM patients. The DCP1A expression in specimens of 56 cases of primary MM (23 cases at TNM stage I-II and 33 cases at TNM stage III-IV) and 43 cases of benign nevi (BN) was measured by quantitative RT-PCR (qRT-PCR), immunohistochemistry, and western blotting...
October 25, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29194095/is-nonmetastatic-cutaneous-melanoma-predictable-through-genomic-biomarkers
#18
Mattia Branca, Samuel Orso, Roberto C Molinari, Haotian Xu, Stéphane Guerrier, Yuming Zhang, Nabil Mili
Cutaneous melanoma is a highly aggressive skin cancer whose treatment and prognosis are critically affected by the presence of metastasis. In this study, we address the following issue: which gene transcripts and what kind of interactions between them can allow to predict nonmetastatic from metastatic melanomas with a high level of accuracy? We carry out a meta-analysis on the first gene expression set of the Leeds melanoma cohort, as made available online on 11 May 2016 through the ArrayExpress platform with MicroArray Gene Expression number 4725...
February 2018: Melanoma Research
https://www.readbyqxmd.com/read/29076952/multiple-primary-melanoma-a-single-centre-retrospective-review
#19
Stephanie Menzies, Rupert Barry, Patrick Ormond
Prognosis has been shown to be worse for patients with multiple primary melanomas than those with a single melanoma. One recent retrospective study showed that older, white men were at higher risk of multiple primary melanomas. In our institution 2057 melanomas were diagnosed between January 1994 and March 2016. We identified 99 (4.8%) patients who had multiple primary melanomas. The average number of melanomas was 2.5 (range: 2-10). The site for first and second melanomas was similar in 30%. We found that subsequent melanomas were more likely to be in situ and thinner in terms of Breslow thickness and Clarks level...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076951/cisplatin-dacarbazine-and-vinblastine-as-first-line-chemotherapy-for-liver-metastatic-uveal-melanoma-in-the-era-of-immunotherapy-a-single-institution-phase-ii-study
#20
Giovanni Schinzari, Ernesto Rossi, Alessandra Cassano, Vincenzo Dadduzio, Michela Quirino, Monica Pagliara, Maria A Blasi, Carlo Barone
No standard therapy is established for metastatic uveal melanoma. Liver involvement in uveal melanoma may lead to organ impairment, which represents a common cause of death. Tumor shrinkage might improve survival by delaying hepatic failure. Since the combination of cisplatin, vinblastine, dacarbazine allowed a high response rate in metastatic cutaneous melanoma, we explored efficacy and safety of this regimen in unresectable liver metastases of uveal melanoma. In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type...
December 2017: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"